MabThera/Rituxan

Triplet approvals for myeloma boost Celgene in Q2

Revlimid could get additional upside if it can claim approval in combination with Roche’s Rituxan (rituximab) for indolent lymphoma, with the results of the MAGNIFY trial due later this year,

New products help lift Roche outlook despite biosimilar onslaught

This was all achieved despite heavy erosion of sales in Europe thanks to biosimilars - the group's total sales fell 4% in the region, with Herceptin revenues down 45% and ... Rituxan shrinking 36%.

Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

The antibody-drug conjugate has been cleared for use alongside the chemotherapy bendamustine and Roche’s blockbuster immunotherapy Rituxan (rituximab) as a regimen for adults with diffuse large B-cell lymphoma ... 1b/2 study in 80 patients with DLBCL

AZ’s Calquence threatens Imbruvica with new leukaemia data

The ASCEND study pitted Calquence against Roche’s Rituxan (rituximab) combined with either Gilead’s Zydelig (idelalisib) or bendamustine, and will be used to support regulatory filings later this year along

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

The data suggests that new antibody could eventually also mount a challenge to Roche’s CD38-targeting Rituxan (rituximab) – also approved as a therapy for DLBCL but facing biosimilar competition – as ... MorphoSys is also carrying out a second

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]